Patents by Inventor Franck Barrat

Franck Barrat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20240033277
    Abstract: This disclosure features methods to treat autoimmune diseases using compounds that activate the unfolded protein response (UPR) and/or compounds that disrupt the tricarboxylic acid (TCA) cycle in immune cells such as plasmacytoid dendritic cells. The disclosure also features method of reducing production of inflammatory cytokines or chemokines by immune cells.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 1, 2024
    Inventors: Vidyanath Chaudhary, Franck Barrat
  • METHODS OF TREATING CANCER, INFECTIOUS DISEASE, AND AUTOIMMUNE DISEASE USING CHEMOKINES
    Publication number: 20220072100
    Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 as well as CCL5 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 10, 2022
    Inventor: Franck Barrat
  • Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
    Patent number: 11197890
    Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 14, 2021
    Assignee: New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Surgery
    Inventor: Franck Barrat
  • METHODS OF TREATING CANCER, INFECTIOUS DISEASE, AND AUTOIMMUNE DISEASE USING CXC CHEMOKINES
    Publication number: 20180193382
    Abstract: The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
    Type: Application
    Filed: December 12, 2017
    Publication date: July 12, 2018
    Inventor: Franck Barrat
  • Human toll-like receptor inhibitors and methods of use thereof
    Patent number: 9868955
    Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: January 16, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Karen L. Fearon, Franck Barrat
  • Methods and compositions for inhibition of immune responses and autoimmunity
    Patent number: 9476053
    Abstract: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: October 25, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Tracy Matray, Cristiana Guiducci
  • Methods of treatment using TLR7 and/or TLR9 inhibitors
    Patent number: 9347064
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 24, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci
  • TLR8 TRANSGENIC ANIMALS
    Publication number: 20160003807
    Abstract: Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.
    Type: Application
    Filed: April 23, 2015
    Publication date: January 7, 2016
    Applicant: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Franck BARRAT, Robert L. COFFMAN, Cristiana GUIDUCCI
  • Human toll-like receptor inhibitors and methods of use thereof
    Patent number: 9228184
    Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 5, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Karen L. Fearon, Franck Barrat
  • METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY
    Publication number: 20150275216
    Abstract: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
    Type: Application
    Filed: February 3, 2015
    Publication date: October 1, 2015
    Inventors: Franck BARRAT, Robert L. COFFMAN, Tracy MATRAY, Cristiana GUIDUCCI
  • HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20150252363
    Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.
    Type: Application
    Filed: September 27, 2013
    Publication date: September 10, 2015
    Inventors: Cristiana Guiducci, Karen L. Fearon, Franck Barrat
  • METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS
    Publication number: 20150203850
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Application
    Filed: November 25, 2014
    Publication date: July 23, 2015
    Inventors: Franck BARRAT, Robert L. COFFMAN, Cristiana GUIDUCCI
  • Transgenic mice expressing human toll-like receptor 8
    Patent number: 9063123
    Abstract: Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic s and methods of use thereof.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 23, 2015
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci
  • Methods and compositions for inhibition of immune responses and autoimmunity
    Patent number: 8962579
    Abstract: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: February 24, 2015
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Tracy Matray, Cristiana Guiducci
  • METHODS AND COMPOSITIONS FOR INHIBITION OF INNATE IMMUNE RESPONSES AND AUTOIMMUNITY
    Publication number: 20150050296
    Abstract: The invention provides immunoregulatory polynucleotides and methods for immunoregulation of individuals using the immunoregulatory polynucleotides.
    Type: Application
    Filed: June 23, 2014
    Publication date: February 19, 2015
    Inventors: Franck BARRAT, Robert L. COFFMAN
  • Methods of treatment using TLR7 and/or TLR9 inhibitors
    Patent number: 8940310
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 27, 2015
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci
  • Methods and compositions for inhibition of innate immune responses and autoimmunity
    Patent number: 8759305
    Abstract: The invention provides immunoregulatory polynucleotides and methods for immunoregulation of individuals using the immunoregulatory polynucleotides.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 24, 2014
    Assignee: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman
  • HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140094504
    Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 3, 2014
    Applicant: Dynavax Technologies Corporation
    Inventors: Cristiana GUIDUCCI, Karen L. FEARON, Franck BARRAT
  • METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS
    Publication number: 20130156814
    Abstract: The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
    Type: Application
    Filed: June 16, 2011
    Publication date: June 20, 2013
    Applicant: Dynavax Technologies Corporation
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci
  • TLR8 TRANSGENIC ANIMALS
    Publication number: 20120252051
    Abstract: Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.
    Type: Application
    Filed: March 29, 2012
    Publication date: October 4, 2012
    Applicant: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Franck Barrat, Robert L. Coffman, Cristiana Guiducci